EUVIMEDEUVIMED entdecken
Systematische ÜbersichtVergleichsstudieNetzwerk-Metaanalyse

Comparative Efficacy of Biologics and Small Molecule in Ulcerative Colitis: A Systematic Review and Network Meta-analysis

Mohammad Shehab, Fatema Alrashed, Abdulwahab Alsayegh, Usama Aldallal, Christopher Ma, Neeraj Narula, Vipul Jairath, Siddharth Singh, Talat Bessissow

Clinical Gastroenterology and Hepatology · 2025-02 · 23 (2) · 250-262

DOI: 10.1016/j.cgh.2024.07.033 ↗

Kurz gefasst

Systematische Übersicht in der Zeitschrift Clinical Gastroenterology and Hepatology, 2025-02. Verfasst von Mohammad Shehab und 8 weiteren Autor:innen. Beteiligte Einrichtung: Division of Gastroenterology, Department of Internal Medicine, Mubarak Alkabeer University Hospital, Kuwait; Department of Pharmacy Practice, Faculty…. Hauptthemen laut MEDLINE: Colitis, Ulcerative, Biological Products. Die Arbeit wurde bisher 67-mal zitiert (Crossref) und nennt 41 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND & AIMS: Treatment options for moderate to severe ulcerative colitis (UC) are increasing rapidly, but the lack of comparative efficacy trials makes treatment choices a clinical challenge. This network-meta-analysis aimed to compare the relative efficacy of biologics and small molecules in achieving remission in patients with moderate to severe UC. METHODS: The literature was searched up to May 2024. Phase 3 placebo or active comparator randomized controlled trials were included. The primary outcome was induction and maintenance of endoscopic improvement (Mayo Endoscopic Score [MES] ≤1). Secondary outcomes were the induction and maintenance of clinical remission, endoscopic (MES = 0) and histological remission. A sub-analysis was performed based on the randomized controlled trial design and previous exposure to biologic therapy. RESULTS: We identified 36 studies that met our inclusion criteria, with 14,270 patients with UC. Upadacitinib ranked highest in inducing clinical remission (99.6%), and endoscopic improvement (99.2%), followed by risankizumab (91.4%) and (82.3%), respectively. In maintenance of endoscopic improvement, upadacitinib ranked first (98.6%) followed by filgotinib 200 mg (79.2%). Risankizumab ranked first in the induction of histological remission (89.4%), followed by guselkumab (88.3%). Upadacitinib ranked first (93.1%) in maintaining histological remission, followed by guselkumab (89.5%). CONCLUSION: Upadacitinib appears to be superior to other therapies in achieving clinical remission, endoscopic improvement and remission, and histological remission. Furthermore, novel biologics such as risankizumab and guselkumab ranked high in achieving these outcomes. This study highlights the efficacy of small molecule drugs and novel selective interleukin-23s as alternatives to other biologics.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Colitis, UlcerativeBiological ProductsHumansTreatment OutcomeRemission InductionRandomized Controlled Trials as TopicHeterocyclic Compounds, 3-RingAntibodies, Monoclonal

Stichwörter der Autor:innen

BiologicsEfficacy of Endoscopic and Histological RemissionSmall MoleculesUC

Substanzen

Biological ProductsrisankizumabupadacitinibHeterocyclic Compounds, 3-RingAntibodies, Monoclonal

Autor:innen und Institutionen

  • Division of Gastroenterology, Department of Internal Medicine, Mubarak Alkabeer University Hospital, Kuwait; Department of Pharmacy Practice, Faculty of Pharmacy, Kuwait University, Jabriya, Kuwait. Electronic address:…
  • Department of Pharmacy Practice, Faculty of Pharmacy, Kuwait University, Jabriya, Kuwait.
  • Department of medicine, School of Medicine, Royal College of Surgeons in Ireland, Medical University of Bahrain, Kingdom of Bahrain.
  • Division of Gastroenterology and Hepatology, Departments of Medicine and Community Health Sciences, University of Calgary, Calgary, Alberta, Canada.
  • Department of Medicine (Division of Gastroenterology) and Farncombe Family Digestive Health Research Institute, McMaster University, Hamilton, Ontario, Canada.
  • Department of Medicine, Division of Gastroenterology, Western University, London, Ontario, Canada; Department of Epidemiology and Biostatistics, Western University, London, Ontario, Canada.

Zitieren

APA

Shehab, M., Alrashed, F., Alsayegh, A., Aldallal, U., Ma, C., Narula, N., Jairath, V., Singh, S., & Bessissow, T. (2025). Comparative Efficacy of Biologics and Small Molecule in Ulcerative Colitis: A Systematic Review and Network Meta-analysis. Clinical Gastroenterology and Hepatology, 23(2), 250-262. https://doi.org/10.1016/j.cgh.2024.07.033

Vancouver

Shehab M, Alrashed F, Alsayegh A, Aldallal U, Ma C, Narula N, et al. Comparative Efficacy of Biologics and Small Molecule in Ulcerative Colitis: A Systematic Review and Network Meta-analysis. Clinical Gastroenterology and Hepatology. 2025;23(2):250-262. doi:10.1016/j.cgh.2024.07.033

BibTeX
@article{Shehab2025,
  author = {Shehab, Mohammad and Alrashed, Fatema and Alsayegh, Abdulwahab and Aldallal, Usama and Ma, Christopher and Narula, Neeraj and Jairath, Vipul and Singh, Siddharth and Bessissow, Talat},
  title = {Comparative Efficacy of Biologics and Small Molecule in Ulcerative Colitis: A Systematic Review and Network Meta-analysis},
  journal = {Clinical Gastroenterology and Hepatology},
  year = {2025},
  volume = {23},
  number = {2},
  pages = {250--262},
  doi = {10.1016/j.cgh.2024.07.033}
}
Kostenlos starten →